In vitro and in vivo analysis shows decreased lactate and alanine as biomarkers in mantle cell lymphoma treatment, indicating potential for targeted therapy.
Motivation: Mantle cell lymphoma (MCL) poses clinical challenges due to resistance to current treatment modalities. Targeting cell metabolism may prove new therapeutic approach to MCL. Goal(s): We evaluated effectiveness of CB-839, a glutaminase inhibitor, against MCL in in vitro and in vivo preclinical studies. Approach: We employed 1H magnetic resonance spectroscopy (1H MRS) imaging and biochemical analyses to investigate the effects of CB-839 on key metabolites in MCL cells, to potentially identify biomarkers of treatment response. Results: Decreases in lactate and alanine concentration emerged as promising biomarkers of response to CB-839 and may potentially serve as biomarkers in MCL patients. Impact: Therapy-mediated decreased intra-tumoral concentrations of lactate and alanine measured by 1H MRS may potentially become early and sensitive biomarkers of glutaminase inhibition in MCL and, likely, other types of malignancies.
No takes yet. Share an insight, caveat, or question.
Nath et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: